John L Vaughn, MD, MS
DownloadHi-Res Photo
About
Biography
John Vaughn is an Assistant Clinical Professor of Medicine. He received his medical degree from Ohio State University. He completed a residency in Internal Medicine at Ohio State University. He completed a fellowship in Hematology & Medical Oncology at NewYork-Presbyterian Weill Cornell Medical Center. He completed a fellowship in Bone Marrow Transplantation at Memorial Sloan Kettering Cancer Center. As a hospitalist, Dr. Vaughn's clinical practice focuses on the management of hospitalized patients with hematologic malignancies, including those receiving bone marrow transplants and cellular therapies. His research focus includes health services and outcomes research. He has a particular interest in the epidemiology of lymphoid malignancies. He participates in the education of medical students through the Yale Interprofessional Longitudinal Clinical Experience.
Appointments
Internal Medicine
Assistant Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2022)
- Fellow
- NewYork-Presbyterian Weill Cornell Medical Center (2021)
- MS
- Cornell University, Clinical Epidemiology & Health Services Research (2021)
- Resident
- The Ohio State University (2017)
- MD
- The Ohio State University (2014)
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- American Board of Internal Medicine
- Original Certification Date
- 2022
Medical Oncology
- Certification Organization
- American Board of Internal Medicine
- Original Certification Date
- 2021
Internal Medicine
- Certification Organization
- American Board of Internal Medicine
- Original Certification Date
- 2017
Research
Overview
Medical Research Interests
Epidemiology; Health Services Research; Lymphoma
ORCID
0000-0001-8122-3852
Research at a Glance
Yale Co-Authors
Frequent collaborators of John L Vaughn's published research.
Publications Timeline
A big-picture view of John L Vaughn's research output by year.
Research Interests
Research topics John L Vaughn is interested in exploring.
Jensa Morris, MD
Bonnie E Gould Rothberg, MD, PhD, MPH, MMM, FACP
Shalin Kothari, MD
Tarsheen Sethi, MD, MSc
12Publications
39Citations
Publications
2024
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
Vaughn J, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N. A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. Blood Cancer Journal 2024, 14: 212. PMID: 39609401, PMCID: PMC11604794, DOI: 10.1038/s41408-024-01194-5.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsIndolent non-Hodgkin lymphomaLymphoma-specific survivalDe novo DLBCLOverall survivalIndolent lymphomaT-FLHistological transformationRelative survivalDe novo diffuse large B-cell lymphomaIndolent non-Hodgkin's lymphoma subtypesDiffuse large B-cell lymphomaReceipt of prior chemotherapyAssociated with inferior survivalLarge B-cell lymphomaMedian follow-up timeStudy of adult patientsLymphoplasmacytic lymphoma/Waldenstrom macroglobulinemiaTransformed indolent lymphomaMarginal zone lymphomaNon-Hodgkin's lymphomaB-cell lymphomaTransformed follicular lymphomaIncidence of HTPopulation-based cohort studyPopulation-based studyEvaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchConceptsPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseAssociation of Hospitalist Care and Outcomes for Patients Electively Admitted for Chemotherapy
Vaughn J, Morris J, Merl M, Gould Rothberg BE. Association of Hospitalist Care and Outcomes for Patients Electively Admitted for Chemotherapy. Journal Of Brown Hospital Medicine 2024, 3 DOI: 10.56305/001c.115906.Peer-Reviewed Original ResearchConceptsLength of stayAnticancer therapyHematologic malignanciesHospitalist careBlood cell count recoveryTumor lysis syndromeQuality outcomesMean discharge timeEfficiency of careOutcomes of length of stayMixed linear regression modelsCount recoveryCare of patientsMethotrexate clearanceTherapy initiationTherapy regimenNo significant differenceTherapy administrationPatientsLinear regression modelsMean timeTherapySignificant differenceImprove qualityMalignancy
2023
Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service
Vaughn J, Merl M, Morris J, Rothberg BE. Association of Hospitalist Care and Outcomes on an Inpatient Elective Anticancer Therapy Service. Blood 2023, 142: 2335. DOI: 10.1182/blood-2023-190824.Peer-Reviewed Original ResearchConceptsHospitalist careTherapy administrationRace/ethnicityTherapy servicesIllness indexSmilow Cancer HospitalTumor lysis syndromeMean discharge timeSignificant differencesQuality outcomesIndex regimenLysis syndromeMedian ageAnticancer regimenMultiple admissionsMethotrexate clearanceCancer HospitalCancer CenterTreatment daysTherapy typeDay 1PatientsAdmissionLymphomaTherapy team
2022
CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era
Vaughn J, Brown S, Papadopoulos E, Jakubowski A, Tamari R, Giralt S, Ponce D, Cho C, Perales M, Shaffer B, Gyurkocza B. CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era. Bone Marrow Transplantation 2022, 57: 1740-1742. PMID: 36076011, DOI: 10.1038/s41409-022-01783-7.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsRacial differences in the survival of mantle cell lymphoma patients in the United States
Vaughn J, Gundepalli S, Epperla N. Racial differences in the survival of mantle cell lymphoma patients in the United States. Hematological Oncology 2022, 40: 479-481. PMID: 35245968, DOI: 10.1002/hon.2984.Peer-Reviewed Original ResearchAltmetric
2021
Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States
Vaughn J, Soroka O, Epperla N, Safford M, Pinheiro L. Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States. Cancer Medicine 2021, 10: 7330-7338. PMID: 34469069, PMCID: PMC8525101, DOI: 10.1002/cam4.4249.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsAutologous hematopoietic cell transplantationNon-Hispanic black patientsHematopoietic cell transplantationNon-Hispanic white patientsDisease-specific factorsBlack patientsWhite patientsLymphoma patientsNon-Hispanic black race/ethnicityEthnic disparitiesPopulation-based cohort studyBlack race/ethnicityCox proportional hazards modelEnd Results (SEER) dataNon-Hodgkin lymphomaPopulation-based dataProportional hazards modelEthnic differencesReceipt of transplantRace/ethnicityCohort studyPrimary outcomeAutologous transplantCell transplantationAutologous transplantationRacial disparities in the survival of patients with indolent non‐Hodgkin lymphomas in the United States
Vaughn J, Spies D, Xavier A, Epperla N. Racial disparities in the survival of patients with indolent non‐Hodgkin lymphomas in the United States. American Journal Of Hematology 2021, 96: 816-822. PMID: 33864695, DOI: 10.1002/ajh.26198.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIndolent non-Hodgkin lymphomaSurvival of patientsHighest excess mortality ratesYoung black patientsBlack patientsNon-Hodgkin lymphomaExcess mortality ratesRelative survivalWhite patientsRacial disparitiesMortality rateExcess deathsLymphoplasmacytic lymphoma/Waldenström macroglobulinemiaFlexible parametric survival modelsAmerican Indians/Alaska NativesMarginal zone lymphomaAsian/Pacific IslandersSignificant racial differencesPaucity of dataAdult patientsDisease histologyPrimary outcomeParametric survival modelsMultivariable analysisWaldenström's macroglobulinemiaSurvival of patients with marginal zone lymphoma in the United States: A population‐based cohort study (2000 to 2017)
Vaughn J, Pinheiro L, Olszewski A, Epperla N. Survival of patients with marginal zone lymphoma in the United States: A population‐based cohort study (2000 to 2017). American Journal Of Hematology 2021, 96: e123-e126. PMID: 33476433, DOI: 10.1002/ajh.26103.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesConfounding Factors, EpidemiologicFemaleHumansKaplan-Meier EstimateLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMortalityPrognosisRituximabSEER ProgramSocial Determinants of HealthUnited StatesYoung Adult
2020
Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus
Gkrouzman E, Smith M, Ghosh N, Laurence J, Seshan S, Vaughn J, Levine A, Bass A, Erkan D. Recurrent Complement-Mediated Thrombotic Microangiopathy in a Patient with Systemic Lupus Erythematosus. HSS Journal ® 2020, 16: 507-514. PMID: 33380989, PMCID: PMC7749916, DOI: 10.1007/s11420-020-09761-9.Peer-Reviewed Original ResearchAltmetric